Levosimendan versus dobutamine in myocardial injury patients with septic shock: A randomized controlled trial

Medical Science Monitor

Volumn 22, Issue , 2016, Pages 1486-1496

  Meng, Jian Biao ^a   Hu, Ma Hong ^a   Lai, Zhi Zhen ^a   Ji, Chun Lian ^a   Xu, Xiu Juan ^a   Zhang, Geng ^a   Tian, Shuyuan ^a  

^a TONGDE HOSPITAL OF ZHEJIANG PROVINCE   (China)

Author keywords

Cardiomyopathies; Fatty acid binding proteins; Hemodynamics; Shock, septic

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; DOBUTAMINE; FATTY ACID BINDING PROTEIN; LEVOSIMENDAN; TROPONIN I; BIOLOGICAL MARKER; HYDRAZONE DERIVATIVE; LACTIC ACID; PYRIDAZINE DERIVATIVE; SIMENDAN;

ADULT; ARTICLE; ARTIFICIAL VENTILATION; BLOOD VOLUME; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; ECHOCARDIOGRAPHY; EXTRAVASCULAR LUNG WATER INDEX; FEMALE; GLOBAL END DIASTOLIC VOLUME INDEX; HEART HEMODYNAMICS; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART MUSCLE INJURY; HEART OUTPUT; HUMAN; INTRATHORACIC BLOOD VOLUME INDEX; LEFT VENTRICULAR STROKE WORK INDEX; MALE; MEAN ARTERIAL PRESSURE; MIDDLE AGED; OUTCOME ASSESSMENT; OXYGEN CONSUMPTION INDEX; OXYGEN DELIVERY INDEX; POSITIVE END EXPIRATORY PRESSURE; RANDOMIZED CONTROLLED TRIAL; SEPTIC SHOCK; STROKE VOLUME INDEX; BLOOD; CARDIAC MUSCLE; COMPARATIVE STUDY; CONTROLLED STUDY; DEMOGRAPHY; HEART LEFT VENTRICLE FUNCTION; HEMODYNAMICS; METABOLISM; MULTIVARIATE ANALYSIS; PATHOLOGY; PATHOPHYSIOLOGY; REGRESSION ANALYSIS; SHOCK, SEPTIC;

BIOMARKERS; DEMOGRAPHY; DOBUTAMINE; FATTY ACID-BINDING PROTEINS; FEMALE; HEMODYNAMICS; HUMANS; HYDRAZONES; LACTIC ACID; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIUM; NATRIURETIC PEPTIDE, BRAIN; PYRIDAZINES; REGRESSION ANALYSIS; SHOCK, SEPTIC; TROPONIN I; VENTRICULAR FUNCTION, LEFT;

EID: 84964834763     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.898457     Document Type: Article

References (51)

1. Tsiotou AG, Sakorafas GH, Anagnostopoulos G et al: Septic shock; Current pathogenetic concepts from a clinical perspective. Med Sci Monit, 2005; 11(3): RA76-85
2. Parrillo JE: Myocardial depression during septic shock in humans. Crit Care Med, 1990; 18: 1183-84
3. Charalampos P, Dimitrios V, Federico F et al: Levosimendan in critical illness: A literature review. J Clin Med Res, 2014; 6: 75-85
4. Ryota S, Michitaka N: A review of sepsis-induced cardiomyopathy. J Intensive Care, 2015; 3: 48
5. Tavernier B, Mebazaa A, Mateo P et al: Phosphorylation-dependent alteration in Ca2+ sensitivity but normal mitochondrial function in septic heart. Am J Respir Crit Care Med, 2001; 163: 362-67
6. Rivers E, Nguyen B, Havstad S et al: Early goal-directed therapy in the treatment of severe sepsis and septic shock. N En J Med, 2001; 345: 1368-77
7. ProCESS Investigators, Yearly DM, Kellum JA, Huang DT et al: A randomized trial of protocol-based care for early septic shock. N Engl J Med, 2014; 370: 1683-93
8. ARISE Investigators, ANZICS Clinical trial Group, Peake SL, Delaney A, Balley M et al: Goal-directed resuscitation for patients with early septic shock. N Engl J Med, 2014; 371: 1496-506
9. Mouncey PR, Osborn TM, Power GS et al: Trial of early, goal-directed resuscitation for septic shock. N Engl J Med, 2015; 372: 1301-11
10. Dellinger RP, Levy MM, Rhodes A et al: Surviving sepsis campaign: International guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med, 2013; 41: 580-637
11. Hernandez G, Bruhn A, Luengo C et al: Effects of dobutamine on systemic, regional and microcirculatory perfusion parameters in septic shock: A randomized, placebo-controlled, double-blind, crossover study. Intensive Care Med, 2013; 39: 1435-43
12. Wilkman E, Kaukonen KM, Pettila V et al: Association between inotrope treatment and 90-day mortality in patients with septic shock. Acta Anaesthesiol Scand, 2013; 57: 431-42
13. Parissis JT, Adamopoulos S, Antoniades C et al: Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure. Am J Cardiol, 2004; 93: 1309-12
14. Landoni G, Mizzi A, Biondi-Zoccai G et al: Levosimendan reduces mortality in critically ill patients. A meta-analysis of randomized controlled studies. Minerva Anestesiol, 2010; 76: 276-86
15. Yi GY, Li JX, Zhang J et al: Repetitive infusion of levosimendan in patients with chronic heart failure: A meta-analysis. Med Sci Monit, 2015; 21: 895-901
16. Spies C, Haude V, Fitzner R et al: Serumcardiac troponin T as a prognostic marker in early sepsis. Chest, 1998; 113: 1055-63
17. Rudiger A, Singer M: Mechanisms of sepsis-induced cardiac dysfunction. Crit Care Med, 2007; 35: 1599-608
18. Charpentier J, Luyt CE, Fulla Y et al: Brain natriuretic peptide: Amarker ofmyocardial dysfunction and prognosis during severe sepsis. Crit Care Med, 2004; 32: 660-65
19. Barraud D, Faivre V, Damy T et al: Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: Comparison with dobutamine and milrinone. Crit Care Med, 2007; 35: 1376-82
20. Ammann P, Fehr T, Minder EI et al: Elevation of troponin I in sepsis and septic shock. Intensive Care Med, 2001; 27: 965-69
21. Witthaut R, Busch C, Fraunberger P et al: Plasma atrial natriuretic peptide and brain natriuretic peptide are increased in septic shock: Impact of interleukin-6 and sepsis-associated left ventricular dysfunction. Intensive Care Med, 2003; 29: 1696-702
22. Kandil E, Burack J, Sawas A et al: B-type natriuretic peptide: A biomarker for the diagnosis and risk stratification of patients with septic shock. Arch Surg, 2008; 143: 242-46
23. Saadeddin SM, Habbab MA, Sobki SH, Ferns SG: Detection of minor myocardial injury after successful percutaneous transluminal coronary angioplasty with or without stenting. Med Sci Monit, 2000; 6: 708-71
24. McLean AS, Huang SJ, Hyams S et al: Prognostic values of B-type natriuretic peptide in severe sepsis and septic shock. Crit Care Med, 2007; 35: 1019-26
25. Tiruvoipati R, Sultana N, Lewis D: Cardiac troponin I does not independently predict mortality in critically ill patients with severe sepsis. Emerg Med Australas, 2012; 24: 151-58
26. Dekker MS, Mosterd A, van 't Hof AW et al: Novel biochemical markers in suspected acute coronary syndrome: Systematic review and critical appraisal. Heart, 2010; 96: 1001-10
27. Lackner KJ: Laboratory diagnostics of myocardial infarction-troponins and beyond. Clin Chem Lab Med, 2013; 51: 83-90
28. Zhang ZC, Dai HY, Yu YH et al: Usefulness of heart-type fatty acid binding protein in patients with severe sepsis. J Crit Care, 2012; 27: 415. e13-18
29. Wu XU, Wu J, Yan XF, Zhang YZ: Enhancement of myocardial function and reduction of injury with levosimendan after percutaneous coronary intervention for acute myocardial infarction: A pilot study. Cardiology, 2014; 128: 202-8
30. Gao WD, Atar D, Liu Y et al: Role of troponin I proteolysis in the pathogenesis of stunned myocardium. Circ Res, 1997; 80: 393-99
31. Rivers EP, McCord J, Otero R et al: Clinical utility of B-type natriuretic peptide in early severe sepsis and septic shock. J Intensive Care Med, 2007; 22: 363-73
32. Court O, Kumar A, Parrillo JE, Kumar A: Clinical review: Myocardial depression in sepsis and septic shock. Crit Care, 2002; 6: 500-8
33. Maeder M, Fehr T, Rickli H, Ammann P: Sepsis-associated myocardial dysfunction: Diagnostic and prognostic impact of cardiac troponins and natriuretic peptides. Chest, 2006; 129: 1349-66
34. Hou ZQ, Sun ZX, Su CY et al: Effect of levosimendan on estimated glomerular filtration rate in hospitalized patients with decompensated heart failure and renal dysfunction. Cardiovasc Ther, 2013; 31: 108-14
35. Feola M, Lombardo E, Taglieri E et al: Effects of levosimendan/furosemide infusion on plasma brain natriuretic peptide, echocardiographic parameters and cardiac output in end-stage heart failure patients. Med Sci Monit, 2011; 17(3): PI17-13
36. Kyrzopoulos S, Adamopoulos S, Parissis JT et al: Levosimendan reduces plasma B-type natriuretic peptide and interleukin 6, and improves central hemodynamics in severe heart failure patients. Int J Cardiol, 2005; 99: 409-13
37. Erbuyun K, Vatansever S, Tok D et al: Effects of levosimendan and dobutamine on experimental acute lung injury in rats. Acta Histochem, 2009; 111: 404-14
38. Hasslacher J, Bijuklic K, Bertocchi C et al: Levosimendan inhibits release of reactive oxygen species in polymorphonuclear leukocytes in vitro and in patients with acute heart failure and septic shock: A prospective observational study. Crit Care, 2011; 15: R166
39. Jo YH, Kim K, Lee JH et al: Heart-type fatty acid-binding protein as a prognostic factor in patients with severe sepsis and septic shock. Am J Emerg Med, 2012; 30: 1749-55
40. Yan GT, Lin J, Hao XH et al: Heart-type fatty acid-binding protein is a useful marker for organ dysfunction and leptin alleviates sepsisinduced organ injuries by restraining its tissue levels. Eur J Pharmacol, 2009; 616: 244-50
41. Tanaka T, Hirota Y, Sohmiya K et al: Serum and urinary human heart fatty acid-binding protein in acute myocardial infarction. Clin Biochem, 1991; 24: 195-201
42. Haikala H, Nissinen E, Etemadzadeh E et al: Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol, 1995; 25: 794-801
43. Ikonomidis I, Parissis JT, Paraskevaidis I et al: Effects of levosimendan on coronary artery flow and cardiac performance in patients with advanced heart failure. Eur J Heart Fail, 2007; 9: 1172-77
44. Michaels AD, McKeown B, Kostal M et al: Effects of intravenous levosimendan on human coronary vasomotor regulation, left ventricular wall stress, and myocardial oxygen uptake. Circulation, 2005; 111: 1504-9
45. Latva-Hirvela J, Kyto V, Saraste A et al: Effects of levosimendan in experimental acute coxsackievirus myocarditis. Eur J Clin Invest, 2009; 39: 876-82
46. Yilmaz MB, Yalta K, Yontar C et al: Levosimendan improves renal function in patients with acute decompensated heart failure: Comparison with dobutamine. Cardiovasc Drugs Ther, 2007; 21: 431-35
47. Fotbolcu H, Duman D: A promising new inotrope: Levosimendan. Anadolu Kardiyol Derg, 2010; 10: 176-82
48. Zager RA, Johnson AC, Lund S et al: Levosimendan protects against experimental endotoxemic acute renal failure. Am J Physiol Renal Physiol, 2006; 290: F1453-62
49. Morelli A, De Castro S, Teboul JL et al: Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med, 2005; 31: 638-44
50. Matejovic M, Krouzecky A, Radej J, Novak I: Successful reversal of resistent hypodynamic septic shock with levosimendan. Acta Anaesthesiol Scand, 2005; 49: 127-28
51. Morelli A, Donati A, Ertmer C et al: Levosimendan for resuscitating the microcirculation in patients with septic shock: A randomized controlled study. Critical Care, 2010; 14: R232